

# **A general method for optimal design of individual and population univariate and multivariate pharmacokinetic experiments**

**Kayode Ogungbenro and Leon Aarons**  
**Centre for Applied Pharmacokinetic Research**  
**School of Pharmacy and Pharmaceutical Sciences**  
**The University of Manchester**  
**Manchester, UK**

# Introduction

- PK – Time course of concentration of drug and metabolites in body fluids
- PD – Collection of data to characterise pharmacological effects
  - surrogate marker, biomarker, enzyme activity or clinical endpoints
- Pharmacokinetic study – Univariate or Multivariate
  - Univariate – PK, PD
  - Multivariate – PK/PD, drug and metabolites, multi-drug (cancer and tuberculosis), multi-organ (WBPBPK)
- Pharmacokinetic multivariate study
  - Balanced
  - Unbalanced

# Introduction

- Population pharmacokinetics (PPK) is widely used in drug development
- PPK study design – Elementary designs, sampling times, number of subjects
- Optimal PPK study design gives the best parameter estimates
- Two approaches to optimal design of PPK
  - Simulation
  - Model (FIM) – Cramer-Rao inequality, inverse of FIM lower bound of the variance-covariance of any unbiased estimator of the parameters
    - Prior knowledge about parameter/variability values - previous studies, pilot study
    - Optimise some criterion function of likelihood within given constraints, D-optimality: Minimise uncertainty associated with parameter estimates

# Introduction - FIM

- Theory of experimental design – Fisher, 1920  
Rothamsted Agricultural Experimental Station
  - Considerable amount of work on methodology and application especially in engineering
- PK models present peculiar problem –  
nonlinear models
  - Individual univariate PK models – FIM is defined
  - Individual multivariate – FIM is defined for balanced design
  - Population univariate – FIM is defined
  - Population multivariate - FIM is defined for balanced design

# Aim

- Develop a general method for individual and population univariate and multivariate PK models that will address existing problems such
  - Unbalanced design – Individual and population multivariate
  - Covariance terms (off diagonal elements) in the omega – Population multivariate

# FIM – Individual and Population Univariate

Fixed Effects (Individual)

$$y_j = f(\theta, t_j) + \varepsilon_j \quad j = 1, \dots, n$$

$$\Psi = [\theta_1, \dots, \theta_p, \sigma_1^2, \sigma_2^2]$$

$$F(\Psi, \xi_i) = E\left(-\frac{\partial^2 l(\Psi; y_i)}{\partial \Psi \partial \Psi^T}\right)$$

Mixed Effects (Population)

$$y_{ij} = f(\theta_i, t_{ij}) + \varepsilon_{ij} \quad j = 1, \dots, n, i = 1, \dots, N$$

$$g(\theta, b_i) = \theta + b_i$$

$$\Omega = \begin{bmatrix} \omega_{11} & \omega_{12} & \cdot \\ \omega_{12} & \omega_{22} & \cdot \\ \cdot & \cdot & \omega_{pp} \end{bmatrix}$$

$$n_\omega = p(p+1)/2$$

$$\Psi = [\theta_1, \dots, \theta_p, \omega_{11}, \omega_{12}, \dots, \omega_{1p}, \omega_{22}, \omega_{23}, \dots, \omega_{2p}, \omega_{pp}, \sigma_1^2, \sigma_2^2]$$

$$F(\theta, \xi)_{ab} = \frac{\partial f(\theta, \xi)}{\partial \Psi_a}^T V^{-1} \frac{\partial f(\theta, \xi)}{\partial \Psi_b} + \frac{1}{2} \text{tr} \left( \frac{\partial V}{\partial \Psi_a} V^{-1} \frac{\partial V}{\partial \Psi_b} V^{-1} \right)$$

$(p+2) \times (p+2)$

$$V = \text{diag}(\sigma_1^2 + \sigma_2^2 f(\theta, \xi)^2)$$

$$V \cong \frac{\partial f^T(\beta, \xi_i)}{\partial b^T} \Omega \frac{\partial f(\beta, \xi_i)}{\partial b^T} + \text{diag}(\sigma_1^2 + \sigma_2^2 f(\theta, \xi_i)^2)$$

# FIM – Individual and Population Multivariate

## Fixed Effects (Individual)

$$y_{mj} = f_m(\theta, t_j) + \varepsilon_{mj}$$

$$j = 1, \dots, n, m = 1, \dots, M$$

$$\mathbf{y} = \begin{bmatrix} y_1' \\ y_2' \\ \vdots \\ y_M' \end{bmatrix}$$

$$\varepsilon_m \rightarrow \sigma_{m1}, \sigma_{m2}$$

$$\Sigma = \left\{ \tau_{qm} \right\}_{1 \leq q, m \leq M}$$

$$\varepsilon \sim MVN(0, V)$$

$$V = \begin{bmatrix} V_{11} & \dots & V_{1M} \\ \vdots & \ddots & \vdots \\ V_{M1} & \dots & V_{MM} \end{bmatrix} (M * n) \times (M * n)$$

$$V_{qm}, R_{qm} \rightarrow n \times n$$

$$V_{qm}(j, l) \Big|_{j=l} = \left\{ \tau_{qm} * \sqrt{(\sigma_{q1}^2 + (\sigma_{q2}^2 * f_q(\theta, t_j)^2)) * (\sigma_{m1}^2 + (\sigma_{m2}^2 * f_m(\theta, t_j)^2))} \right\}_{\substack{1 \leq q, m \leq M \\ 1 \leq j, l \leq n}}$$

$$V_{qm}(j, l) \Big|_{j \neq l} = \{0\}_{\substack{1 \leq q, m \leq M \\ 1 \leq j, l \leq n}}$$

## Mixed Effects (Population)

$$y_{imj} = f_m(\theta_i, t_{ij}) + \varepsilon_{imj}$$

$$j = 1, \dots, n, m = 1, \dots, M, i = 1, \dots, N$$

$$\mathbf{y}_i = \begin{bmatrix} y_{i1}' \\ y_{i2}' \\ \vdots \\ y_{iM}' \end{bmatrix}$$

$$\varepsilon_i \sim MVN(0, R_i)$$

$$R_i = \begin{bmatrix} R_{11} & \dots & R_{1M} \\ \vdots & \ddots & \vdots \\ R_{M1} & \dots & R_{MM} \end{bmatrix} (M * n) \times (M * n)$$

# FIM – Individual and Population Multivariate

Fixed Effects (Individual)

Mixed Effects (Population)

$$F(\Psi, \xi_i) = E\left(-\frac{\partial^2 l(\Psi; y_i)}{\partial \Psi \partial \Psi^T}\right)$$

$$\Psi = [\theta', \Pi', \zeta']$$

$$\theta = [\theta_1, \dots, \theta_p]$$

$$\Pi = [\omega_{11}, \dots, \omega_{1p}, \omega_{22}, \dots, \omega_{2p}, \omega_{33}, \dots, \omega_{3p}, \dots, \omega_{pp}]$$

$$\zeta = [\sigma_{11}^2, \dots, \sigma_{1M}^2, \sigma_{21}^2, \dots, \sigma_{2M}^2]$$

$$F(\Psi, \xi_i)_{az} = \left\{ J_a^T V^{-1} J_z + \frac{1}{2} \text{tr} \left( \frac{\partial V}{\partial \Psi_a} V^{-1} \frac{\partial V}{\partial \Psi_z} V^{-1} \right) \right\}$$

$$(p + 2 * M) \times (p + 2 * M)$$

$$(p + n_\omega + 2 * M) \times (p + n_\omega + 2 * M)$$

$$J_a = [J_{a1}', J_{a2}', \dots, J_{aM}'] \quad J_{am} = \frac{\partial f_m(\Psi, \xi_i)}{\partial \Psi_a}$$


$$V = \text{Var}(y_i) \cong U' \Omega U + R$$

$$U_k = [U_{k1}', U_{k2}', \dots, U_{kM}'] \text{ and } U_{km} = \frac{\partial f_m^T(\theta, b_i, \xi_i)}{\partial b_i} \Big|_{b_i=0}$$

# FIM – Univariate and Multivariate

- Expressions for unbalanced designs have been developed
- Expressions incorporated into sampling windows determination
- Full omega matrix has been accounted for in the expressions
- These expressions have been implemented in PopDes
  - Balanced design
  - Diagonal omega matrix

# PopDes – Windows Interface



# PopDes - Options

Design	Local/Bayesian		Model		Optimisation	Efficiency	Sampling Windows
	Local	Bayesian	Library	External			
Individual Univariate	√	√	√	√	√	√	-
Individual Multivariate	√	√	-	√	√	√	-
Population Univariate	√	-	√	√	√	√	√
Population Multivariate	√	-	-	√	√	√	√

Key: √ means that function is available and – (dash) means function is not available for the design.

# Example

## PK/PD Model (2 responses)

$$y_{PKij_{PK}} = f_{PK}(\theta_i, t_{ij_{PK}}) + \varepsilon_{PKij_{PK}} \rightarrow \sigma_{PK1}, \sigma_{PK2}$$

$$f_{PK}(\theta_i, t_{ij_{PK}}) = \frac{Dose}{V_i} e^{(Cl_i * t_{ij_{PK}} / V)} \quad \longrightarrow \text{One cmpt IV bolus model}$$

$$y_{PDij_{PD}} = f_{PD}(\theta_i, t_{ij_{PD}}) + \varepsilon_{PDij_{PD}} \rightarrow \sigma_{PD1}$$

$$f_{PD}(\theta_i, t_{ij_{PD}}) = \frac{emax_i * f_{PK}(\theta_i, t_{ij_{PD}})}{e50_i + f_{PK}(\theta_i, t_{ij_{PD}})} \quad \longrightarrow \text{Emax model}$$

### Parameters

$$\theta = [Cl, V, emax, e50]$$

$$\Omega = \begin{bmatrix} \Omega_{Cl} & \Omega_{ClV} & 0 & 0 \\ \Omega_{ClV} & \Omega_V & 0 & 0 \\ 0 & 0 & \Omega_{e50} & \Omega_{e50emax} \\ 0 & 0 & \Omega_{e50emax} & \Omega_{emax} \end{bmatrix}$$

$$\sigma^2 = [\sigma_{PK1}^2, \sigma_{PK2}^2, \sigma_{PD1}^2]$$

(4)

(6)

(3)

12

# Example

$$\theta_i = \theta e^{b_i} \longrightarrow \text{Exponential IIV}$$

$$\theta = [3.46, 10, 7.5, 10] \quad \Omega = \begin{bmatrix} 0.0625 & 0.03 & 0 & 0 \\ 0.03 & 0.04 & 0 & 0 \\ 0 & 0 & 0.16 & 0.07 \\ 0 & 0 & 0.07 & 0.0625 \end{bmatrix} \quad \sigma^2 = [0.25, 0.1, 0.09]$$

[Correlation  $C_l$  and  $V = 0.6$ ,  $e50$  and  $emax$  0.7]

$$\Sigma = \begin{bmatrix} 1 & 0 \\ 0 & 1 \end{bmatrix} \longrightarrow \text{No correlation between responses}$$

Dose=200mg every 12 hours

One group of 50 subjects

Sampling designs: 3 PK and PD sample (same time) after the first dose, 3 PD samples after the second dose (9 samples, 3 PK and 6 PD

# Example

Optimisation: Modified Fedorov exchange algorithm, step size 0.05

Optimisation: Two designs; with and without off diagonal elements

Simulation and Estimation: Two designs, NONMEM (FOCE/LAPLACE) - 100

Statistics: Relative error (RE), % mean relative error (bias)  
% root mean square error (precision)


$$RE = \Psi_{est} - \Psi_{true} / \Psi_{true}$$

$$\%MRE = \frac{1}{n} \left( \sum_{j=1}^n \left( \frac{\Psi_{est_i} - \Psi_{true}}{\Psi_{true}} * 100 \right) \right)$$

$$\%RMSE = \left[ \frac{1}{n} \left( \sum_{j=1}^n \Psi_{est_i} - \Psi_{true} \right)^2 \right]^{\frac{1}{2}} * 100$$


# Results - Optimisation

Omega with diagonal elements



0.05, 2.25, 9.6, 12.05, 15.25, 21.75 hr


Omega without diagonal elements




0.05, 0.95, 11.7, 15.2, 16, 22 hr

# Results - Simulation

Omega with off diagonal elements



Omega without off diagonal elements




# Results - Simulation

Parameters	%MRE		%RMSE	
	NW	NO	NW	NO
$Cl$	<b>0.17</b>	<b>0.35</b>	<b>11.56</b>	<b>14.18</b>
$V$	<b>0.08</b>	<b>0.08</b>	<b>28.62</b>	<b>29.04</b>
$ec50$	<b>-6.61</b>	<b>-5.68</b>	<b>72.55</b>	<b>108.49</b>
$emax$	<b>-0.33</b>	<b>-0.08</b>	<b>38.44</b>	<b>53.49</b>
$ome(Cl)$	<b>0.82</b>	<b>-1.82</b>	<b>1.57</b>	<b>1.57</b>
$ome(ClV)$	<b>-1.77</b>	<b>-6.24</b>	<b>1.01</b>	<b>0.98</b>
$ome(V)$	<b>-2.08</b>	<b>-4.85</b>	<b>0.90</b>	<b>0.87</b>
$ome(ec50)$	<b>-1.44</b>	<b>-6.09</b>	<b>5.09</b>	<b>10.43</b>
$ome(ec50emax)$	<b>-0.91</b>	<b>-8.04</b>	<b>2.35</b>	<b>3.95</b>
$ome(emax)$	<b>-0.84</b>	<b>-5.16</b>	<b>1.47</b>	<b>2.02</b>
$sig1PK$	<b>2.42</b>	<b>6.10</b>	<b>0.30</b>	<b>0.25</b>
$sig2PK$	<b>2.16</b>	<b>1.04</b>	<b>6.52</b>	<b>6.07</b>
$sig1PD$	<b>0.40</b>	<b>-0.24</b>	<b>0.96</b>	<b>0.91</b>

# Results - Simulation

Percentage coefficient of variation of the standard errors



# Summary

- A general method that deals with
  - unbalanced problem in population multivariate problem has been described
  - as well as off diagonal elements in the omega matrix
- The FIM can be used for
  - optimisation – D,c,A,G optimality
  - Bayesian
  - Sampling windows determination
- The CVSE are within the NONMEM range